Breaks Categories: News

MondayFeb 10, 2020 10:33 am

NetworkNewsBreaks – Crexendo, Inc. (CXDO) Named to 2020 OTCQX Best 50

Crexendo (OTCQX:CXDO), an award-winning premier provider of cloud communications, UCaaS (Unified Communications as a Service), call center, collaboration services, and other cloud business services that are designed to provide enterprise-class cloud services to any size business at affordable monthly rates, today announced it has been named to the 2020 OTCQX(R) Best 50. An annual ranking of the top 50 U.S. and international companies traded on the OTCQX market, the OTCQX Best 50 is calculated based on an equal weighting of one-year total return and average daily dollar volume growth in the previous calendar year. Companies in the 2020 OTCQX Best…

Continue Reading

MondayFeb 10, 2020 10:09 am

NetworkNewsBreaks – Nightfood Holdings Inc. (NGTF) Eyes Tremendous New Market Segment as Pregnancy Care Providers Begin Recommending Nightfood to Expecting Moms

Nightfood Holdings (OTCQB: NGTF), the award-winning ice cream company addressing America’s $50 billion-dollar nighttime snacking problem, today announced that pregnancy care providers have begun recommending Nightfood to their pregnant clients, and the Company intends to aggressively pursue and serve this valuable market segment. With a well-documented link between pregnancy and ice cream cravings, pregnant women have specific nutritional needs that happen to correlate with the unique benefits of Nightfood’s formulation. These include extra calcium, magnesium, zinc, fiber, and protein, which are all recommended, while sugars should be kept down. Nightfood also has ingredients to minimize heartburn, which can be a…

Continue Reading

MondayFeb 10, 2020 9:39 am

NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Collaborates with Major Universities for the Evaluation of SofPulse(R) for Orthopedic Surgeries

Endonovo Therapeutics (OTCQB: ENDV) today announced the evaluation of its SofPulse(R) device at major universities for orthopedic surgeries. Endonovo’s FDA-Cleared SofPulse(R) is a non-invasive device utilized for the reduction of postoperative pain and edema and represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures. “We are pleased to announce SofPulse(R) is now being evaluated at major medical universities. We believe this is a unique opportunity for SofPulse(R) to be evaluated, and upon completion and approval, be used as a standard of healthcare moving forward,” Endonovo Therapeutics CEO Alan Collier said…

Continue Reading

MondayFeb 10, 2020 9:30 am

NetworkNewsBreaks – PowerBand Solutions Inc. (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) Inks Agreement with Citation Capital Management

PowerBand Solutions (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) this morning announced that it has reached an agreement with Citation Capital Management to aid in procuring extensive funding options for loans and leases to be approved through PowerBand's leasing operations in the United States. Per the release, the agreement will advance PowerBand’s mission to raise a total of $1 billion in credit facilities to utilize by providing consumers and dealers access to loans or leases on vehicles acquired through the company’s cloud-based transaction platform. “This is another milestone in PowerBand's strategy to meet our goal of aggregating $1-billion in credit facilities…

Continue Reading

MondayFeb 10, 2020 8:30 am

NetworkNewsBreaks – National Storm Recovery Inc. (NSRI) Acquires Mulch Manufacturing Inc., Forming Sustainable Green Team

National Storm Recovery (OTC: NSRI) this morning announced that it has acquired Mulch Manufacturing, Inc. Following the identification of significant synergies and strategic benefits involved, the company acquired the 35-year-old industry leader and innovator via a share exchange. “With Mulch Manufacturing’s national and international distribution, its sales contracts with many big box retailers and the increase in production and packaging capacity it provides, this strategic acquisition has positioned us as - The Sustainable Green Team,” National Storm Recovery CEO Tony Raynor stated in the news release. To view the full press release, visit http://nnw.fm/3Nrk8 About National Storm Recovery National Storm…

Continue Reading

FridayFeb 07, 2020 1:59 pm

NetworkNewsBreaks – Allied Motion Technologies Inc. (NASDAQ: AMOT) Featured in ROTH Equity Research Report

Allied Motion Technologies (NASDAQ: AMOT) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “We initiate AMOT with a Buy rating and $57 price target. Our investment thesis is driven by expected organic growth of 7-8% due to previously announced auto contracts and double digit growth in A&D and Medical segments. Revenue growth should lead to operating leverage as SG&A costs moderate allowing for increased FCF and debt reduction. Acquisitions and AMOT’s One Allied program remains an important lever for expansion by acquiring technology and customers and integrating them into its global…

Continue Reading

FridayFeb 07, 2020 1:50 pm

NetworkNewsBreaks – Mitek Systems, Inc. (NASDAQ: MITK) Featured in ROTH Equity Research Report

Mitek Systems (NASDAQ: MITK) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Mobile deposit strength drove MITK’s topline beat, driven by a price increase (as expected), which also flowed into stronger gross margins and profits. Overall 1Q results were good, although growth continues to decelerate, notably transactional SaaS. FY20 guidance was unchanged, but the heightened risk profile from patent IP remains applicable with many moving pieces and potential long timelines. Maintain Neutral rating and $9 price target.” To request access to the full report, visit http://nnw.fm/DXCr3 About Mitek Mitek (NASDAQ: MITK)…

Continue Reading

FridayFeb 07, 2020 1:45 pm

NetworkNewsBreaks – PC Connection, Inc. (NASDAQ: CNXN) Featured in ROTH Equity Research Report

PC Connection (NASDAQ: CNXN) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “We are transferring coverage of CNXN to ROTH Capital Research and placing shares Under Review to refocus research resources. Prior to placing shares Under Review, CNXN was Buy rated with a $51 price target. Effective with note, previous estimates, rating and price target for CNXN should no longer be relied on.” To request access to the full report, visit http://nnw.fm/DXCr3 About Connection PC Connection, Inc. and its subsidiaries, dba Connection(R), is a Fortune 1000 company headquartered in Merrimack, NH.…

Continue Reading

FridayFeb 07, 2020 12:56 pm

NetworkNewsBreaks – Evolus, Inc. (NASDAQ: EOLS) Featured in Mizuho Securities Research Report

Evolus (NASDAQ: EOLS) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “Evolus is a commercial-stage biopharma company focused exclusively on the aesthetics market, with lead asset Jeuveau now approaching the one-year anniversary of its US launch. We are encouraged by the uptake of Jeuveau to date and, based on conversations with thought leaders and our Mizuho proprietary aesthetics market survey, we see significant room for upside as Jeuveau competes in one of the more attractive markets in biopharma. We also appreciate the legal overhang on the stock but our channel…

Continue Reading

FridayFeb 07, 2020 12:53 pm

NetworkNewsBreaks – Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report

Satsuma Pharmaceuticals (NASDAQ: STSA) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are BUY rated on Satsuma given the potential we see for STS101 in the acute treatment of migraines. Phase 3 data is expected in 2H 2020, with regulatory filing in late 2021 and potential market entry in late 2022/early 2023. We see STS101 as a differentiated asset delivering dihydroergotaminemesylate (‘DHE’) intranasally that can be used by patients who do not respond to current treatment options. We estimate probability-adjusted sales of ~$300MM in 2028 along with a 70%…

Continue Reading